Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 5Sarcoma 2Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Gliosarcoma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Desmoplastic Small Round Cell Tumor 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 9gallium 68 PSMA-11 7Specimen Handling 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4enzalutamide 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Standard of Care 2Radiation 2Positron Emission Tomography Computed Tomography 2HhAntag691 2Abiraterone Acetate 268Ga-DKFZ-PSMA-11 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2xentuzumab 1trastuzumab biosimilar HLX02 1tislelizumab 1teprotumumab 1tazemetostat 1relugolix 1pertuzumab 1palbociclib 1olaparib 1niraparib 1gallium citrate 1eribulin 1entrectinib 1darolutamide 1cobimetinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Prostatic Neoplasms × Irinotecan × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡